Grail Inc ( (GRAL) ) has released its Q4 earnings. Here is a breakdown of the information Grail Inc presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
GRAIL, Inc. is a healthcare company specializing in early cancer detection through advanced technologies like next-generation sequencing and machine learning, aiming to reduce cancer’s global impact. In its latest financial results, GRAIL announced significant growth, with U.S. Galleri test revenue up 45% to $108.6 million in 2024 and a moderated cash burn extending its financial runway into 2028. Key highlights include a 35% increase in total revenue and strategic moves such as TRICARE coverage and integration with Quest Diagnostics, enhancing test accessibility. Despite reporting a net loss of $2.0 billion for the year due to goodwill and intangible asset impairments, the company made substantial operational improvements, including a 44% increase in adjusted gross profit. Looking ahead, GRAIL is poised for continued growth in 2025 with ongoing study progress and strategic initiatives aimed at enhancing its market presence.